Exciting Treatment Advances in Upper Tract Urothelial Cancer: Seth P. Lerner, MD, FACS

Substantial developments are under way in the treatment of upper tract urothelial cancer (UTUC). Seth P. Lerner, MD, FACS, recently spoke with i3 Health about mitomycin gel (JelmytoTM, UroGen Pharma), now FDA approved as the first agent specifically indicated for the treatment of low-grade UTUC. In this second installment of his interview, Dr. Lerner, principal investigator of the OLYMPUS study, on which the mitomycin gel approval was based, discusses research advances in the treatment of both l...
Continue reading

Mitomycin Gel for Low-Grade Upper Tract Urothelial Cancer: Seth P. Lerner, MD, FACS

Upper-tract urothelial cancer (UTUC) is a rare cancer that often needs to be treated with radical surgery, typically entailing complete removal of the affected kidney, ureter, and bladder cuff. Mitomycin C formulated with a reverse thermal hydrogel (JelmytoTM, UroGen Pharma), recently approved by the FDA as the first agent specifically indicated for the treatment of low-grade UTUC, will now allow some patients to keep a kidney that would otherwise have needed to be removed. In this interview wit...
Continue reading

Multiple Myeloma, Vitamin D Deficiency, and Race

In patients with multiple myeloma, vitamin D deficiency negatively impacts overall survival in white patients but not in African American patients.Multiple myeloma is a hematologic malignancy that affects plasma cells in the bone marrow, causing damage to the immune system, surrounding organs, and bones. Because vitamin D plays a crucial role in bone health, maintaining an appropriate level of this vitamin is particularly important for patients with multiple myeloma. However, little research had...
Continue reading

Birth Defects and Pediatric Cancer: An Interview With Philip J. Lupo, PhD, MPH

‚ÄčIn their recently published study, Philip J. Lupo, PhD, MPH, and colleagues found that both chromosomal anomalies and nonchromosomal birth defects significantly increase a child's risk of receiving a cancer diagnosis before his or her 18th birthday. In this interview with i3 Health, Dr. Lupo discusses his findings and the future directions of this research.Can you comment on the significance of your results concerning the link between birth defects and pediatric cancer risk?Philip J. Lupo, PhD,...
Continue reading

Pediatric Brain Tumors: Cognitive Effects in Adulthood

Children with central nervous system (CNS) tumors have good prognoses; 75% will live at least five years after diagnosis. Unfortunately, a recent study has shown that these survivors experience neuropsychological problems and lower socioeconomic status later in life compared with their healthy peers.For this study, published in Cancer, the researchers analyzed data on 181 adult survivors of pediatric low-grade gliomas from the Childhood Cancer Survivor Study and compared them with a group of 105...
Continue reading

Copyright © 2020 i3 Health. All rights reserved.